This is a mobile optimized page that loads fast, if you want to load the real page, click this text.

BMT - Beamtree Holdings

Jump to new
Today's 3rd quarter results were very good. 51% yoy growth, 21% profit improvement. Future reminds me of other apps like Aconex. Bought a couple of weeks ago but put a bid in to buy few more.
 
Thanks @Knobby22 for the update. I always thought they had the 'it' , or is that IT, factor and bought early as PKS ...one of those tilts that we all hope comes off. It ran and than wallowed and I eventually sold ... part of a wide ranging cleanout rather than stock specific. Made $4k but gave up more.

Anyway, point is, I find It hard to revisit old girlfriends. Am probably missing out on some upside as I think BMT could own some success in their sector. Will continue to monitor; good luck with yr holding.
 
Dona Ferentes said:
Thanks @Knobby22 for the update. I always thought they had the 'it' , or is that IT, factor and bought early as PKS ...one of those tilts that we all hope comes off.
Click to expand...
... slaking that thirst.


Beamtree completes $5m capital raise to accelerate organic revenue growth.

Beamtree is pleased to announce a successful institutional placement of $5m at $0.25 per share, which received demand significantly above the $5m raised. Funds have been raised from both new and existing institutional shareholders.

The new capital will be used to scale operations and accelerate revenue growth in existing and recently proved revenue generating markets (Saudi Arabia, the UK and North America) and in conjunction with the renewed diagnostic software distribution agreement with Abbott Laboratories Inc. Funds will also be deployed in customer driven innovation of existing and new validated AI clinical decision support technology products.

Specifically, funds deployed will enable scale in key growing health markets such as Saudi Arabia, and the UK and domestically, in the following product segments:
• Diagnostics: increased capability in sales/pre-sales for RippleDown® in global pathology as well as software engineering for our innovation pipeline;
• Coding Assistance and Data Quality: iterative development of our key go to market in key new markets of Saudi Arabia, the UK and North America;
• Clinical Decision Support: sales/pre-sales and integration resources for our AI generated patient deterioration product;
• Data Analytics: innovation and investment in our Knowledge Networks data analytics platform aimed at enhancing the quality improvement programs for our major client, The Health Roundtable in Australia.

Significantly, the funds will also provide funds for pre-sales and integration resources to support the new distribution agreement with Abbott Inc, for Beamtree’s RippleDown® product for Pathology. Specifically:
• Abbott has more than 18,000 clients globally and Beamtree is targeting up to 100 contracts by the end of FY2026 with a minimum annual value of US$120,000 (per contract to BMT).
• Abbott is launching RippleDown® into the US and Asia Pacific regions for the first time in early FY24. This capital raise enhances the company’s confidence in delivering and exceeding its previously stated medium term target of AU$60m annual recurring revenue by 2026. Importantly, the capital is also sufficient to allow the company to deliver cash flow positive returns by the end of FY2024.
 

.
Outlook for FY24
In relation to the new financial year the Company is targeting the following:
• Targeting FY24 organic revenue growth of +20%;
• Continued focus on cost management with cost growth % targeted to be lower than revenue growth %;
• Targeting to deliver a positive operating profit in FY24;



(U2H)
 
are we there yet?
.
Q1 FY24 Trading Highlights:
Beamtree continues to perform in line with previously disclosed FY24 outlook in Q1 FY24 driven by strong customer renewal rates at historical levels of +95% plus continued international new wins. The sales pipeline for the Company continues to develop and mature driven by a strong pipeline of international opportunities in our core overseas markets. These sales opportunities will provide a foundation to the long-term goal of achieving ARR of $60m by the end of 2026.

Key highlights for Q1 FY24 were:
• ARR for Q1 FY24 stands at $23.8m (up from $19.1m Q1 FY23);
• Revenue for Q1 FY24 Group was +23% pcp;
• Significant pipeline wins and milestones achieved in Q1 across all 4 core divisions;
• International revenue growth was +50% pcp with geographic expansion achieved in target markets in Asia, Middle East, UK and Canada;
• Public and Private Healthcare customer wins in Australia achieved;
• Strong momentum in sales pipeline with Abbott Laboratories in Tier 1 and Tier 2 success.


.
used to hold, but sold a few panics ago at 29c ....now 20c
 
Yes, me too. Worth looking at again.
 
trundling along ... meeting targets , but ...

.

.

.
(MIR bought in, recently)
 
I sold out last year Feels like a small fish with some big competition. No market confidence.
 
A very optimistic report.

BMT was 21c when unaudited results came out on 6th, then two days later ran to 30c and now 26.5c.
 
Q1 update out. $0.25 .. up a bit

Key highlights for Q1 FY25 were:
• Group revenue growth of 16% for Q1 FY25 with more than two-thirds of this revenue driven by recurring revenue growth.
• Group recurring revenue growth was 12.4% versus 11.0% for the prior corresponding period. The value of recurring revenue growth increased by 21% Q1 FY25 versus Q1 FY24.
• International revenue growth year to date was more than 35% as the business continues to expand its footprint in target overseas markets (the UK, Canada and the Kingdom of Saudi Arabia ).
• Operating cost growth of 6% year on year compared to 18% for Q1 FY24 with the cost growth primarily driven by ongoing investment in products and people driven capabilities.
• Operating loss of $0.2m in Q1 FY25 versus a loss of $0.8m in Q1 FY24 driven by the increase in recurring revenue growth and disciplined cost management. We expect to deliver a break-even position for the six months to 31 Dec 2024.
• Reduced capitalised software development spend by 40% to ~$0.6m as the large investment projects of FY24 were completed in early Q1 FY25.
• Cash at 30 September 2024 was $4.3m versus $5.0m at 30 June 2024, with the cash outflow broadly relating to capitalised software investment in Q1. Operating cashflow for Q1 was break even compared to a $2.8m operating cash outflow in Q1 FY24.

Outlook
Beamtree continues to have a strong pipeline of opportunities across all its markets and products with this pipeline maturing and supporting the expected acceleration in recurring revenue growth in 2025. The Company reaffirms expected revenue growth of +20% for FY25.

The Company will continue to focus on delivering profitable growth and carefully managing its cost base and product investment to support overseas expansion and the long-term aim of delivering annual recurring revenue of $60m by the end of 2026.
 
You must log in or register to reply here.

Similar threads

TTZ - Total Telcom Inc.
Replies
2
Views
2K
TacoTed
NXS - Next Science
2
Replies
25
Views
6K
Dona Ferentes
Ultimate Acronym List (UAL)
Replies
0
Views
5K
Dividend
Menu
Log in
Register
Cookies are required to use this site. You must accept them to continue using the site. Learn more...